Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in patients with MASH cirrhosis. As we eagerly await the topline results next month, we remain hopeful that belapectin may be a potential new treatment for the large number of patients in the U.S. with compensated cirrhosis, portal hypertension, and which have not developed esophageal varices. These patients represent a large unmet medical need.” Khurram Jamil, M.D., Chief Medical Officer, added, “We are pleased to share that Galectin will present three posters highlighting important data
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingGlobeNewswire
- Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
GALT
Earnings
- 11/14/24 - Beat
GALT
Analyst Actions
- 8/16/24 - HC Wainwright
GALT
Sec Filings
- 11/14/24 - Form 8-K
- 11/14/24 - Form 8-K
- 11/14/24 - Form 10-Q
- GALT's page on the SEC website